Crinetics Pharmaceuticals, Inc.
CRNX
Rang in aandelen
#2239
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Aandeelprijs
$84.95
Laatst gesynchroniseerd: 2026-09-01
Marktkapitalisatie
$9.00B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
100.12%
Land
US
Handel Crinetics Pharmaceuticals, Inc. (CRNX)
Categorie
Healthcare
EPS voor Crinetics Pharmaceuticals, Inc. (CRNX)
EPS per June 2026 TTM: $-5.05
Volgens de laatste financiële rapporten en de aandelenkoers van Crinetics Pharmaceuticals, Inc. is de huidige EPS van het bedrijf (TTM) $-5.05. Eind 2023 had het bedrijf een EPS van $-3.69, een stijging ten opzichte van de EPS van 2022 die $-3.15 bedroeg.
EPS-geschiedenis van Crinetics Pharmaceuticals, Inc. van 2016 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-5.05 | 36.86% |
| 2024 | $-3.69 | 0.00% |
| 2023 | $-3.69 | 17.14% |
| 2022 | $-3.15 | 12.50% |
| 2021 | $-2.80 | 15.70% |
| 2020 | $-2.42 | 18.05% |
| 2019 | $-2.05 | -8.07% |
| 2018 | $-2.23 | 237.88% |
| 2017 | $-0.66 | 53.49% |
| 2016 | $-0.43 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | -442.97% |
US
|
|
| $-7.98 | 58.02% |
US
|
|
| $-5.29 | 4.75% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -649.31% |
NL
|
